Geron (GERN)
(Delayed Data from NSDQ)
$4.29 USD
-0.33 (-7.14%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $4.28 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Geron (GERN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.81 | $10.00 | $4.50 | 47.40% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Geron comes to $6.81. The forecasts range from a low of $4.50 to a high of $10.00. The average price target represents an increase of 47.4% from the last closing price of $4.62.
Analyst Price Targets (8 )
Broker Rating
Geron currently has an average brokerage recommendation (ABR) of 1.38 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.38 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 12.5% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.38 | 1.38 | 1.38 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/10/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/7/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
6/7/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
5/3/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
4/30/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Hold |
4/29/2024 | Cowen & Co. | Tara Bancroft | Not Available | Strong Buy |
3/15/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.38 |
ABR (Last week) | 1.38 |
# of Recs in ABR | 8 |
Average Target Price | $6.81 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.11 |